

**Remarks**

Applicants have amended the specification at page 5, line 34 to page 6, line 10 to replace “SEQ ID NO: 18” with “SEQ ID NO: 17”. The SEQ ID NO: on page 5, line 35 was mistakenly identified in the originally filed specification as SEQ ID NO: 16. Subsequently, SEQ ID NO: 16 was amended to recite “SEQ ID NO: 18” on April 27, 2006 in order to conform the specification to the Sequence Listing of October 24, 2005. Currently, Applicants have amended the specification on page 5 to replace “SEQ ID NO: 18” with “SEQ ID NO: 17”, to conform the specification to the Replacement Sequence Listing submitted herewith. Support for the amendment to the specification to replace SEQ ID NO: 18 with SEQ ID NO: 17 (an amino acid sequence for the mouse HR protein) is found in pages 5 and 27-28 of the originally filed specification. Specifically, page 5 of the specification indicates that SEQ ID NO: 17 includes amino acid residues 490-1182 of the C-terminal portion of mouse HR protein. This is further supported on page 28 of the specification as set forth in the Replacement Sequence Listing section.

Applicants have also amended page 7, line 9 to correct an obvious grammatical error in the originally filed specification.

Applicants have also amended the specification at page 28, lines 18-20 to replace “from the published sequence (SEQ ID NO: 17)” with “from the published sequence (SEQ ID NO: 18)”. In regards to the amendment to replace “SEQ ID NO: 17” with “SEQ ID NO: 18”, support for the amendment is found in pages 27-28 of the originally filed specification. Specifically, page 28 of the originally filed specification identifies SEQ ID NO: 102. SEQ ID NO: 102 refers to a published nucleotide sequence for the mouse HR gene, which is described in a Begona reference cited on pages 27-28 of the specification, the relevant parts of which were incorporated by reference (See page 33, lines 28-29). The nucleotide sequence for the mouse HR gene was mistakenly identified as SEQ ID NO: 102 in the originally filed application on page 28, lines 18-19. Subsequently, SEQ ID NO: 102 was amended to recite “SEQ ID NO: 17” on October 24, 2005 in order to conform the specification to the Sequence Listing of October 24, 2005. As set forth above, Applicants have amended the specification on page 28 to replace “SEQ ID NO: 17” with “SEQ ID NO: 18”, which corresponds with the Replacement Sequence Listing submitted herewith.

In addition, Applicants have also amended the specification at page 28, lines 19-20 to replace “Amino acid number 1 of SEQ ID NO: 18” with “Amino acid number 1 of SEQ ID NO: 17”. In regards to the amendment to replace “SEQ ID NO: 18” with “SEQ ID NO: 17”, support for the amendment is found in pages 27-28 of the originally filed specification. Specifically, page 28 of the originally filed specification identifies SEQ ID NO: 103. SEQ ID NO: 103 refers to a published amino acid sequence for the mouse HR protein, which is described in a Begona reference cited on pages 27-28 of the specification, the relevant parts of which were incorporated by reference (See page 33, lines 28-29). The amino acid sequence for the mouse HR protein was mistakenly identified as SEQ ID NO: 103 in the originally filed application on page 28, lines 19-20. Subsequently, SEQ ID NO: 103 was amended to recite “SEQ ID NO: 18” on October 24, 2005 in order to conform the specification to the Sequence Listing of October 24, 2005. As set forth above, Applicants have amended the specification on page 28 to replace SEQ ID NO: 18 with “SEQ ID NO: 17”, which conforms to the Replacement Sequence Listing submitted herewith.

Applicants have also amended the specification at page 28, lines 15-18 to correct nucleotide positions, which were incorrectly identified in the original specification as “nucleotide position 2166”, “nucleotide position 2611”, and “nucleotide position 2916”. Applicants further submit that a preliminary amendment filed on October 20, 2005 mistakenly amended “nucleotide position 2166” to recite “321”; “nucleotide position 2611” to recite “756”, and “nucleotide position 2916” to recite “1076”. Applicants submit that in accordance with the Replacement Sequence Listing filed herewith, “nucleotide position 2166” (currently part of the record as 321) has been amended to recite “2165”; “nucleotide position 2611” (currently part of the record as 756) has been amended to recite “2600”; and “nucleotide position 2916” (currently part of the record as 1076) has been amended to recite “2915”. Applicants submit that no new matter has been introduced by the amendments to the nucleotide positions. Applicants submit that the correct nucleotide positions were determined by counting the nucleotides in the HR gene sequence on page 7719 of the Begona reference, the relevant parts of which were incorporated by reference (See page 33, lines 28-29).

If the undersigned can be of assistance to the Examiner in addressing any additional issues to advance the application to a condition of allowance, please contact the undersigned at the number set forth below.

Respectfully submitted,

Dated: 10/20/2009



Christine R. Ethridge  
Registration No. 30,557

K&L Gates LLP  
Henry W. Oliver Building  
535 Smithfield Street  
Pittsburgh, Pennsylvania 15222  
Telephone: (412) 355-8619  
Facsimile: (412) 355-6501